A number of interesting findings in early follow up of this randomized controlled trial on one type of transcatheter aortic valve against conventional surgery: the mechanics of the valve and the incidence of complete heart block, to name but a few. We await the longer follow up.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
TAVR (TAVI)
March 18, 2019
March 14, 2019
On Wednesday March 13, the ACC Quality Summit announced in New Orleans that beginning in mid-2019, hospitals performing transcatheter valve repair and replacement will be able to apply for the American College of Cardiology's new Transcatheter Valve Certification.
March 8, 2019
Patient Care and General Interest
The American Heart Association has released a scientific statement summarizing emerging knowledge about sensitization after heart transplant.
February 27, 2019
Kofler and colleagues evaluated prospectively-measured psoas muscle area in more than 1,000 patients who underwent transcatheter aortic valve replacement at two centers. Indexed psoas area was independently associated with 30-day and follow-up mortality.
February 6, 2019
In this prospective single-institution study, functional status trajectory one year after intervention was compared for transcatheter (TAVR) versus surgical aortic valve replacement (SAVR). A moderate/large decline compared to preintervention status occurred in 23% of TAVR patients and 4% of SAVR patients. A frailty index, postoperative delirium, a
January 4, 2019
Edwards Lifesciences announced that the SAPIEN 3 Ultra system has received US Food and Drug Administration approval for transcatheter aortic valve replacement in severe, symptomatic aortic stenosis patients who are determined to be at intermediate or greater risk of open-heart surgery.
December 18, 2018
The authors, using the STS/ACC TVT Registry, analyzed the the occurrence of patient-prosthesis mismatch (PPM) in 62,215 patients enrolled between 2014 and 2017. They found that severe and moderate PPM occurred in 12% and 25% of patients, respectively.
December 18, 2018
This study analyzed the cost-effectiveness of TAVR versus SAVR in 3110 intermediate-risk aortic stenosis patients from the PARTNER-2 trial. Using a Markov model, the authors found that TAVR is economically dominant from the perspective of lifetime cost-effectiveness in the US healthcare system.
December 14, 2018
Patient Care and General Interest
Truly remote percutaneous coronary intervention was performed in five human patients at Apex Heart Institute in Ahmedabad, India.
November 27, 2018
Hebeler and colleagues hypothesized that the inclusion of measures of frailty might improve the prediction of mortality one-year after transcatheter aortic valve replacement (TAVR).